预约演示
Soligenix and Silk Road sign deal for Behçet’s disease treatment rights
2023-05-02
临床结果临床2期引进/卖出上市批准
Soligenix has the right to purchase the topical formulation. Credit: AdoreBeautyNZ from Pixabay.
Soligenix has signed an exclusive option agreement with Silk Road Therapeutics for the right to acquire Pentoxifylline (PTX) topical formulation intended to treat mucocutaneous ulcers in Behçet’s disease (BD) patients.
Soligenix did not divulge the terms of the deal.Silk Road TherapeuticsPentoxifylline (PTX)mucocutaneous ulcersBehçet’s disease (BD)
Recommended Reports
ReportsLOA and PTSR Model - Satralizumab in Demyelinating Diseases GlobalData
ReportsLOA and PTSR Model - (Cilnidipine + Tadalafil) in Raynauds Disease GlobalData
BD is a rare multisystem inflammatory vasculitis, which currently has no treatment.
The disease is characterised CilnidipineecuTadalafilers iRaynauds Diseasea, skin, genitalia and eyes.
It is estimated to impact around 18,000 people in the US and 80,000 in Europe, while 1,000,000 people are living with the disease across the globe.
Soligenix repmultisystem inflammatory vasculitis effective than colchicine in a Phase II proof-of-concept (POC) trial. BD patients were randomised to receive either standard-of-care colchicine therapy or colchicine in combination with topical PTX.
Patients applied the PTX mucoadhesive grecurrent ulcersday for up to 14 days for treating current mouth ulcers. They also used their standard colchicine regimen.
It was found that 83% of patients treated with PTX had index ulcer area shrinkage by day two, as against 19% of patients treated with only colchicine.
Soligenix, pain scores wPTX also reported to be reduced in patiecolchicineing PTX. No serious adverse events were observed among the patients.colchicinecolchicine
Soligenix president and CEO Christopher Schaber said: “The novel muco-adherent topical formulationmouth ulcersthe potential to fill a significcolchicinen the current treatment armamentarium for BD, where a clear unmet medical need exists.
“General agreement amongst treating physicians PTXthat currenulcernt-line treatment/management options, such as oral and topical steroids, colchiciney ineffective and have a number of potentially significant safety issues when used long-term.
“When transpainning to the more effective therapies, like biologics such as adalimumab and apremilast, the only approved treatment in BD, these longer-term safety concerns persist and are associated with a much higher financial burden to patients and/or payers in treating this lifelong condition.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。